169 related articles for article (PubMed ID: 9625452)
1. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis.
Akimoto S; Furuya Y; Akakura K; Ito H
Endocr J; 1998 Feb; 45(1):97-104. PubMed ID: 9625452
[TBL] [Abstract][Full Text] [Related]
2. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
Akimoto S; Akakura K; Shimazaki J
Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of the serum levels of bone formation and bone resorption markers in prostate cancer patients with bone metastasis.
Akimoto S; Inomiya H; Furuya Y; Akakura K; Ito H
Eur Urol; 1998 Aug; 34(2):142-7. PubMed ID: 9693250
[TBL] [Abstract][Full Text] [Related]
4. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
5. Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis: comparison with the extent of disease (EOD) grade.
Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
Prostate; 1999 Jan; 38(1):28-34. PubMed ID: 9973106
[TBL] [Abstract][Full Text] [Related]
6. [Studies of type I collagen related substances as bone metastatic markers of prostate carcinoma with special regard to serum carboxyterminal propeptide of type. I. Procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and Urinary deoxypyridinoline levels].
Imai T; Honda M; Maeda S; Hosoya Y; Arai T; Sumi S; Umeda H; Yano M; Koga F; Arai K; Yoshida K
Nihon Hinyokika Gakkai Zasshi; 1998 Apr; 89(4):484-91. PubMed ID: 9597867
[TBL] [Abstract][Full Text] [Related]
7. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen.
Kataoka A; Yuasa T; Kageyama S; Tsuchiya N; Habuchi T; Iwaki H; Narita M; Okada Y; Yoshiki T
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):480-4. PubMed ID: 16909972
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
Fukumitsu N; Uchiyama M; Mori Y; Kishimoto K; Nakada J
Ann Nucl Med; 2003 Jun; 17(4):297-303. PubMed ID: 12932112
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
[TBL] [Abstract][Full Text] [Related]
11. Collagen derived serum markers in carcinoma of the prostate.
Rudnicki M; Jensen LT; Iversen P
Scand J Urol Nephrol; 1995 Sep; 29(3):317-21. PubMed ID: 8578275
[TBL] [Abstract][Full Text] [Related]
12. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
Katagiri M; Fukunaga M; Ohtawa T; Harada T
World J Surg; 1996 Sep; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
[TBL] [Abstract][Full Text] [Related]
13. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase.
Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
Int J Urol; 1997 Nov; 4(6):572-5. PubMed ID: 9477186
[TBL] [Abstract][Full Text] [Related]
14. Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients.
Akimoto S; Okumura A; Fuse H
Endocr J; 1998 Apr; 45(2):183-9. PubMed ID: 9700471
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer.
Westerhuis LW; Delaere KP
Eur J Clin Chem Clin Biochem; 1997 Feb; 35(2):89-94. PubMed ID: 9056749
[TBL] [Abstract][Full Text] [Related]
16. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.
Kylmälä T; Tammela TL; Risteli L; Risteli J; Kontturi M; Elomaa I
Br J Cancer; 1995 May; 71(5):1061-4. PubMed ID: 7734300
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer.
Noguchi M; Yahara J; Noda S
Urology; 2003 May; 61(5):993-8. PubMed ID: 12736022
[TBL] [Abstract][Full Text] [Related]
18. Influence of osteoarthritis on serum marker levels of bone formation and resorption in patients with benign prostatic hypertrophy.
Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
Int J Urol; 1997 Nov; 4(6):580-2. PubMed ID: 9477188
[TBL] [Abstract][Full Text] [Related]
19. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
20. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer.
Koga H; Naito S; Koto S; Sakamoto N; Nakashima M; Yamasaki T; Noma H; Kumazawa J
Prostate; 1999 Apr; 39(1):1-7. PubMed ID: 10221259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]